Clinical trials: Asthma Patients
Asthma
A Study in Patients With Asthma
The purpose of the present study is to demonstrate the higher efficacy of Foster® NEXThaler® 100/6 extra fine (two inhalations b.i.d.) versus Seretide® Accuhaler® 250/50 (one inhalation b.i.d.), in terms of pulmonary function…
- Trial name
- NELSON (NCT01570478)
- Testing
- Foster® NEXThaler® 100/6 µg/unit dose, Seretide® Accuhaler® 250/50 µg/actuation
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to…
- Trial name
- NCT00394121
- Testing
- Fluticasone propionate/formoterol fumarate
- Where
- 28 sites in Germany, Hungary and 3 more
- Volunteers
- 400 people
- Sponsor
- SkyePharma AG
Asthma
CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.
Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice
- Trial name
- NCT00714038
- Where
- 93 sites in Denmark
- Volunteers
- 2,122 people
- Sponsor
- AstraZeneca
Asthma
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total…
- Trial name
- NCT02554786
- Testing
- Indacaterol acetate/Mometasone furoate, Mometasone furoate, Salmeterol xinafoate/fluticasone propionate
- Where
- 388 sites in United States, Bulgaria and 22 more
- Volunteers
- 2,216 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a…
- Trial name
- NCT01347060
- Testing
- fluticasone propionate/salmeterol xinafoate combination, inhaled corticosteroids
- Volunteers
- 17,448 people
- Sponsor
- GlaxoSmithKline
Asthma
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be…
- Trial name
- NCT00546520
- Testing
- Ciclesonide
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Asthma
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.
- Trial name
- NCT02031640
- Testing
- Beclomethasone dipropionate, Albuterol/salbutamol
- Where
- 131 sites in United States, Germany and 2 more
- Volunteers
- 1,113 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.) and fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 88 mcg b.i.d and placebo…
- Trial name
- NCT01397162
- Testing
- Fluticasone propionate, BI 54903
- Where
- 41 sites in United States
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Bronchial Asthma
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combination given with the conventional CFC…
- Trial name
- NCT00528723
- Testing
- salbutamol 100 mcg, BDP/salbutamol HFA pMDI, BDP/salbutamol CFC pMDI
- Where
- 25 sites in Italy, Russia and 2 more
- Volunteers
- 180 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients
The purpose of this study is to demonstrate that CHF 1535 NEXT DPI® is non-inferior to the corresponding dose of CHF 1535 pMDI and superior to marketed beclomethasone DPI 100 µg in terms of average pre-dose morning Peak…
- Trial name
- Neptune (NCT01345916)
- Testing
- CHF 1535 100/6 NEXT DPI® 2 months, CHF 1535 100/6 pMDI 2 months, BDP DPI 2 months
- Where
- Poland
- Volunteers
- 932 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics
This is a pivotal trial that will examine therapeutic equivalence (BE) of a new generic fixed-dose combination product containing fluticasone propionate 100 mcg / salmeterol 50 mcg (as xinafoate salt) and reference listed drug…
- Trial name
- NCT02496715
- Testing
- Fluticasone propionate 100 mcg / salmeterol 50 mcg, Generic fluticasone propionate 100 mcg / salmeterol 50 mcg
- Sponsor
- Actavis Inc.
Asthma
Study on Patterns of Care in Mild Asthmatic Patients
The PRIME study is an observational, Real World Evidence study designed to collect the type of treatments that are currently prescribed to patients with mild asthma and to collect relevant clinical data that could reflect the…
- Trial name
- PRIME (NCT04598555)
- Where
- 59 sites in Germany, Italy and 2 more
- Volunteers
- 981 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).
- Trial name
- NCT02134028
- Testing
- Dupilumab
- Where
- 365 sites in United States, Argentina and 25 more
- Volunteers
- 2,282 people
- Sponsor
- Sanofi
Asthma
Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
The primary objective of the study is to compare the tolerability of Symbicort® Turbuhaler® 160/4.5 μg 10 inhalations with terbutaline Turbuhaler® 0.4 mg 10 inhalations for 3 days on top of Symbicort® Turbuhaler® 160/4.5 μg 1…
- Trial name
- NCT00837967
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma
Asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory conditions involving the small airways with airflow limitations resulting from genetic and environmental interactions.
- Trial name
- NCT03344406
- Testing
- Telephonic interviews, E-RS: COPD, Supplemental asthma items
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma
- Trial name
- NCT00152984
- Testing
- Tiotropium inhalation capsules
- Where
- 68 sites in Belgium, Canada and 6 more
- Volunteers
- 472 people
- Sponsor
- Boehringer Ingelheim
Asthma
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma
The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult…
- Trial name
- NCT00393952
- Testing
- Fluticasone propionate/Formoterol fumarate 250/10, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- SkyePharma AG
Asthma
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels
The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels.
- Trial name
- NCT03771040
- Testing
- Masitinib
- Where
- 5 sites in Argentina, Malaysia and 3 more
- Volunteers
- 347 people
- Sponsor
- AB Science
Asthma
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)
The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast…
- Trial name
- NCT00092989
- Testing
- montelukast sodium
- Volunteers
- 650 people
- Sponsor
- Organon and Co
Severe Asthma
Observational Retrospective Study on Clinical Outcomes of Patients Receiving Benralizumab in Spain.
Primary Objectives: 1. To describe the demographic and baseline characteristics in patients with severe eosinophilic asthma in Spain who received at least one dose of Benralizumab, after its marketing authorization 2.
- Trial name
- ORBE-II (NCT04648839)
- Where
- Spain
- Volunteers
- 221 people
- Sponsor
- AstraZeneca